← Eichor
Study identifier: NCT07160231 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases

Condition: Rheumatoid Arthritis (RA) · Psoriatic Arthritis (PsA) · Axial Spondyloarthritis (AxSpA)  ·  Sponsor: Sint Maartenskliniek

PhasePhase 4
Planned participants200
Who can joinAll sexes, 16 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to assess the effectiveness of a disease activity guided dose reduction strategy of Janus kinase inhibitor (JAKi) compared to disease activity guided JAKi continuation in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who are in a state of low disease activity or remission while on JAKi. The main question it aims to answer is: Is a disease activity guided dose reduction strategy for JAKi not inferior in terms of efficacy compared to disease activity guided JAKi continuation in patients with RA/PsA/axSpA that are currently in a low disease activity/remission state? Researchers will compare a disease activity guided dose reduction strategy for JAKi to disease activity guided JAKi continuation in patients with RA/PsA/axSpA that are currently in a low disease activity/remission state to see if a disease activity guided dose reduction strategy for JAKi is not inferior in terms of efficacy compared to disease activity guided JAKi continuation. Participants will: * Follow a JAKi dose reduction strategy or will continue using JAKi in the same dose * Study (telemonitoring) visits are planned every 3 months * At every visit, patients are asked to complete patient-reported outcomes that assess daily functioning, health-related quality of life, pain, fatigue, productivity loss, medical consumption and medication adherence.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (7)

Sint Maartenskliniek NijmegenNijmegen, Gelderland, NetherlandsRecruiting
Maastricht UMC+Maastricht, Limburg, NetherlandsNot Yet Recruiting
Elisabeth-TweeSteden Ziekenhuis TilburgTilburg, North Brabant, NetherlandsNot Yet Recruiting
Medisch Spectrum TwenteEnschede, Overijssel, NetherlandsNot Yet Recruiting
Isala ZwolleZwolle, Overijssel, NetherlandsNot Yet Recruiting
Erasmus MCRotterdam, South Holland, NetherlandsNot Yet Recruiting
Maasstad ziekenhuisRotterdam, South Holland, NetherlandsNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07160231